Luminita LATEA, Ştefania L. NEGREA, Sorana D. BOLBOACA

Effects of valsartan and nebivolol on blood pressure, QT dispersion and left ventricular hypertrophy in hypertensive patients

Amaç: Bu çalışmanın amacı valsartan ve nebivololun antihipertansif etkilerini ve bu ilaçların hipertansif hastaların tedavisinde QT dağılımı ve sol ventrikül hipertrofsi üzerine etkilerini analiz etmektir. Yöntemler: Sol ventrikül hipertrofsi (SVH) bulunan haff/orta hipertansiyonlu hastalarda 6 ay süreli takip içeren prospektif bir çalışma düzenlendi. Hastalar rastgele olarak Valsartan (80-160 mg/gün) veya Nebivolol (5-10 mg/gün) gruplarına alındı. Çalışma grubu 55’i Valsartan grubu, 53’ü Nebivolol grubunda olmak üzere toplam 108 hastadan oluşturuldu. Bulgular: Valsartan grubunda ortalama sistolik kan basıncı (SKB) 152±17 mmHg (bazal)’den 132±17 mmHg (takip)’e değişti (p

Hipertansif hastalarda valsartan ve nebivololun, kan basıncı, QT dağılımı ve sol ventrikül hipertrofsi üzerine etkileri

Objectives: The aim of this study was to analyze the antihypertensive effect of Valsartan and Nebivolol and their effects on QT dispersion and left ventricular hypertrophy (LVH) in the treatment of naive hypertensive patients. Methods: A prospective study with a six-month follow-up was conducted on hypertensive patients with LVH and mild/ moderate essential hypertension. The patients were randomly assigned to Valsartan (80 to 160 mg/day) or Nebivolol (5 to 10 mg/day) groups. The study group consisted of 108 patients, 55 in the Valsartan group and 53 in the Nebivolol group. Results: The range of mean systolic blood pressure (SBP) varied from 152±17 (baseline) to 132±17 mmHg (follow-up) in the Valsartan group (p<0.001); from 146±13 to 125±14 mmHg in the Nebivolol group (p<0.001). The decrease in mean diastolic blood pressure (DBP) was 9.5±2.5 mmHg in the Valsartan group and 12.3±5.0 mmHg in the Nebivolol group. A signifcant reduction in QT and corrected QT (Bazett’s formula) dispersion was observed in both groups, with a slightly higher reduction in the Valsartan group. Echocardiography showed a de- crease in the left ventricle mass (LVM) indices (p<0.05) in both groups with a greater reduction in the Valsartan group. Conclusion: Valsartan treatment was as effective as Nebivolol in reducing the 24 hour- SBP after a 6 month treatment. Nebivolol treatment proved to be superior to Valsartan in reducing DBP. Both therapies were effective in reducing the LVH; Valsartan proved to be superior to Nebivolol in reducing the QT interval indexes in relation to blood pressure and LVM reduction.

PDF

___

1. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13:82-8.
2. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation 1987;75:126-33.
3. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratifcation in the long QT syndrome. N Engl J Med 2003;348:1866-74.
4. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-70.
5. Oikarinen L, Nieminen MS, Viitasalo M, et al. LIFE Study Investigators. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy. Hypertension 2004;43:1029-34.
6. Rasmussen KG, Hooten WM, Dodd ML, Ryan DA.QTc dispersion on the baseline ECG predicts arrhythmias during electroconvulsive therapy. Acta Cardiol 2007;62:345-7.
7. Yildirir A, Batur MK, Oto A. Hypertension and arrhythmia: blood pressure control and beyond. Europace 2002;4:175-82.
8. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115 41-6.
9. Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fbrillation prevention. Vasc Health Risk Manag 2008;4: 67-73.
10. Lim PO, Nys M, Naas AA, et al. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999;33:713-8.
11. Sampson UK, Pfeffer MA, McMurray JJV, et al. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. Eur Heart J 2007;28: 685-91.
12. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res 1998;38:419-31.
13. Sule SS, Frishman W. Nebivolol: new therapy update. Cardiol Rev 2006;14:259-64.
14. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation ß-adrenergic blocker. Ann Pharmacother 2006;40:1353-60.
15. Pessina AC. Metabolic effects and safety profle of nebivolol. J Cardiovasc Pharmacol 2001;38:S33-S35.
16. Toda N. Vasodilating ß-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003;100:215-34.
17. Ambrosioni E, Borghi C. Tolerability of nebivolol in headtohead clinical trials versus other cardioselective β-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev 2005;12:27-35.
18. European Society of Hypertension - European Society if Cardiology Guidelines Committee. 2007 Ecuropean Society of Hypertension - European Society of Cardiology guidelines for the Management of Arterial Hypertension. Eur Heart J 2007;28:1462-536.
19. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55: 613-8.
20. Schiller NB, Shah PM, Crawford M, et al.Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
21. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977:55:613-8.
22. Drugan T, Bolboacă S, Jäntschi L, Achimaş Cadariu A. Binomial Distribution Sample Confdence Intervals Estimation 1. Sampling and Medical Key Parameters Calculation. Leonardo El J Pract Technol 2003;3:47-74.
23. Bolboacă S, Jäntschi L, Achimaş Cadariu A. Binomial Distribution Sample Confdence Intervals Estimation 2. Proportion-like Medical Key Parameters. Leonardo El J Pract Technol 2003;3:75-110.
24. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005;18:1060-6.
25. Balanescu S. Galinier M., Fourcade J, et al. Correlation between QT interval dispersion and ventricular arrhythmia in hypertension. Arch Mal Coeur Vaiss 1996;89:987-90.
26. De Bruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: The Rotterdam Study. Circulation 1998;97:467-72.
27. Miyajima K, Minatoguchi S, Ito Y, et al. Reduction of QTc dispersion by the Angiotensin II receptor Blocker Valsartan May Be Related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res 2007;30:307-13.
28. Brooksby P, Robinson PJ, Segal R, et al. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. Lancet 1999;354: 395-6.
29. Davila DF, Donis JH, Odreman R, et al. Patterns of left venmtricular hypertrophy in essential hypertension: should echocardiography guide the pharmacological treatment? Int J Cardiol 2008; 124: 134-8.
30. Galinier M., Balanescu S., Fourcade J, et al. Prognostic value of ventricular arrhythmias in systemic hypertension. J Hypertens 1997;15:1779-83.
31. Gavras I, Gavras H. The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens 2000;13:512-7.
32. Refaat S, El-Ghaffar NA, El-Rahman Negm HA, Yousri T. The role of aldosterone in myocardial dysfunction of Egyptian patients with essential hypertension. Arch Med Sci 2008;4:161-6.
33. Van den Meiracker AH, Boomsma F. The angiotensin II - sympathetic nervous system connection. J Hypertens 2003;21:1453-4.
34. Rocha RM, Silva GV, Perin EC, et al. Effects of carvedilol therapy on QT interval dispersion in congestive heart failure. Tex Heart Inst J 2003;30:176-9.
35. Galetta F, Franzoni F, Magagna A, et al. Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother 2005;59:15-9.
36. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol 2002;90:1107-12.
37. Prisant ML. Nebivolol: Pharmacologic profle of an ultraselective, vasodilatory ß1-blocker. J Clin Pharmacol 2008;48:225-39.
38. Sawhney V, Kapoor B, Sharma S, et al. Effects of atenolol and nebivolol on blood pressure and on ECG in patients of stage 1-hypertension–a comparative study. J Clin Diag Research 2008;2:925-31.
39. Pagani M, Lucini D. Autonomic dysregulation in essential hypertension: insight from heart rate and arterial pressure variability. Auton Neurosci 2001;90:76-82.